logo-loader
viewAthersys

Athersys CEO highlights progress of lead therapy MultiStem to help stroke patients

Athersys Inc (NASDAQ: ATHX) CEO Dr. Gil Van Bokkelen together with patient and stroke victim Sharon Thomas joined Proactive Investors in New York to discuss how MultiStem, Athersys' lead therapy, is progressing through the drug-development cycle.

Thomas was treated with MultiStem when the drug was in Phase 2. It has since progressed to Phase 3 with FDA Fast Track designation. What's more, a separate clinical program evaluating MultiStem cell therapy for the treatment of Acute Respiratory Distress Syndrome has received Fast Track designation.

Quick facts: Athersys

Price: 3.01 USD

NASDAQ:ATHX
Market: NASDAQ
Market Cap: $592.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences PLC's chairman discusses the potential for its 'crown...

Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott why he feels its drug Foralumab is the 'crown jewel' in the company's portfolio. It's a fully-human monoclonal anti-CD3 antibody which is being developed for treatment of...

4 hours, 30 minutes ago

2 min read